Cargando…

Complete remission of critical neurohistiocytosis by vemurafenib

OBJECTIVE: To describe a patient with life-threatening brainstem neurohistiocytosis who recovered completely upon targeted treatment with the V600E mutation-specific BRAF inhibitor vemurafenib. METHODS: We report clinical, histiologic, genetic, and sequential imaging findings, including fluorodeoxyg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Euskirchen, Philipp, Haroche, Julien, Emile, Jean-François, Buchert, Ralph, Vandersee, Staffan, Meisel, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345630/ https://www.ncbi.nlm.nih.gov/pubmed/25745636 http://dx.doi.org/10.1212/NXI.0000000000000078

Ejemplares similares

Targeted treatment of brainstem neurohistiocytosis guided by urinary cell-free DNA
por: Hunt, David, et al.
Publicado: (2016)

Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report
por: Tzoulis, Charalampos, et al.
Publicado: (2015)

Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study
por: Donadieu, Jean, et al.
Publicado: (2019)

Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing BRAF(V600E) -Mutated Erdheim–Chester Disease: A Case Report
por: Razanamahery, Jérôme, et al.
Publicado: (2022)

Blue-Violet Light Irradiation Dose Dependently Decreases Carotenoids in Human Skin, Which Indicates the Generation of Free Radicals
por: Vandersee, Staffan, et al.
Publicado: (2015)

Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH
por: Evseev, Dmitry, et al.
Publicado: (2023)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Anaphylactic reactions to polyethylene glycol-containing bowel cleansing preparations after Moderna COVID-19 vaccination
por: Schreiner, Maximilian, et al.
Publicado: (2021)

Awakening with amantadine from a persistent vegetative state after subarachnoid haemorrhage
por: Lehnerer, Sophie Mirabell, et al.
Publicado: (2017)

Design and Development of Fluorescent Vemurafenib Analogs for In Vivo Imaging
por: Mikula, Hannes, et al.
Publicado: (2017)

Scurvy in a patient on vemurafenib
por: Gerstenblith, Meg R., et al.
Publicado: (2014)

A STATement on Vemurafenib-Resistant Melanoma
por: Hartsough, Edward J., et al.
Publicado: (2013)

Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance
por: Peng, Jianyu, et al.
Publicado: (2023)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

PD-1/PD-L1 expression is frequent and correlated with lymphocyte density in Erdheim-Chester disease
por: Charlotte, Fréderic, et al.
Publicado: (2022)

Metastatic melanoma and vemurafenib: novel approaches
por: De Mello, Ramon Andrade
Publicado: (2012)

Delayed-onset vemurafenib-induced panniculitis
por: Vance, Stephen L., et al.
Publicado: (2017)

A Rare Cause of Uveitis: Vemurafenib
por: Sızmaz, Selçuk, et al.
Publicado: (2018)

The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma
por: Cui, Hongmei, et al.
Publicado: (2021)

Remission of Invasive, Cancer Stem-Like Glioblastoma Xenografts Using Lentiviral Vector-Mediated Suicide Gene Therapy
por: Huszthy, Peter C., et al.
Publicado: (2009)

Vemurafenib and Dabrafenib Downregulates RIPK4 Level
por: Madej, Ewelina, et al.
Publicado: (2023)

RASopathic Skin Eruptions during Vemurafenib Therapy
por: Rinderknecht, Jeannine D., et al.
Publicado: (2013)

Immune Thrombocytopenia Revealing Enriched IgG-4 Peri-Renal Rosai-Dorfman Disease Successfully Treated with Rituximab: A Case Report and Literature Review.
por: Razanamahery, Jerome, et al.
Publicado: (2021)

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts
por: Kemper, Kristel, et al.
Publicado: (2015)

Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma
por: Hagen, Brenda, et al.
Publicado: (2014)

Sorafenib sensitizes melanoma cells to vemurafenib through ferroptosis
por: Tang, Fengjie, et al.
Publicado: (2020)

Low‐dose vemurafenib in hairy cell leukemia patients with active infection
por: Bohn, Jan‐Paul, et al.
Publicado: (2019)

Highly proliferative anal neuroendocrine carcinoma: molecular and clinical features of a rare, recurrent case in complete remission
por: Juhlin, Carl Christofer, et al.
Publicado: (2020)

Cardiac involvement resolution is frequent and associated with improved outcome in Erdheim-Chester disease
por: Azoulay, Lévi-Dan, et al.
Publicado: (2023)

Vemurafenib and cutaneous adverse events - report of five cases
por: Silva, Giselle de Barros, et al.
Publicado: (2015)

Safety and efficacy of vemurafenib in end stage renal failure
por: Iddawela, Mahesh, et al.
Publicado: (2013)

Correction: RASopathic Skin Eruptions during Vemurafenib Therapy
por: Rinderknecht, Jeannine D., et al.
Publicado: (2013)

DNA repair inhibition by UVA photoactivated fluoroquinolones and vemurafenib
por: Peacock, Matthew, et al.
Publicado: (2014)

Targeting MEK in vemurafenib-resistant hairy cell leukemia
por: Caeser, Rebecca, et al.
Publicado: (2018)

Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells
por: Osrodek, Marta, et al.
Publicado: (2020)

Complete remission in metastatic hepatocellular carcinoma
por: Ben Kridis, Wala, et al.
Publicado: (2023)

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)

In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors
por: Żołek, Teresa, et al.
Publicado: (2023)

Histiocytosis and the nervous system: from diagnosis to targeted therapies
por: Cohen Aubart, Fleur, et al.
Publicado: (2021)

Vemurafenib resistance reprograms melanoma cells towards glutamine dependence
por: Hernandez-Davies, Jenny E, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hhssr6lvc55tukefos19qst4b4